AAV8 SOX4 Gene Silencing for Alagille Bile Duct Paucity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alagille syndrome (ALGS) causes severe bile duct paucity leading to intrahepatic cholestasis and liver failure, with no effective treatments beyond liver transplantation, which is hindered by donor shortages and complications.
Innovation Solution
Administering AAV8 vectors containing shRNA targeting SOX4 to reduce its expression and activity, improving bile duct development and liver function in ALGS models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver transplantation is performed to treat ALGS liver failure, then patient survival is improved, but donor availability is limited and complications increase
Solution Approach 1:
The patent uses AAV8 vectors as an intermediary delivery system to transport shRNA against SOX4 into liver cells. This viral vector mediator enables the therapeutic effect without requiring donor organs, resolving the contradiction between improving patient survival and limited donor availability
Solution Approach 2:
The patent extracts and suppresses the harmful SOX4 gene expression through shRNA-mediated RNA interference. By taking out the detrimental genetic factor (SOX4 overexpression) that causes bile duct paucity, the treatment improves bile duct development and liver function without needing transplantation
2Reliability
If liver transplantation is performed to treat ALGS, then liver function is restored, but post-transplant complications and immunosuppression risks increase
Solution Approach 1:
The patent applies preliminary action by suppressing SOX4 expression before severe liver damage occurs. The shRNA therapy prevents the progression to end-stage liver disease, restoring liver function through disease modification rather than replacement, thereby avoiding post-transplant complications and immunosuppression
Solution Approach 2:
The AAV8-shRNA complex serves as an intermediary therapeutic agent that delivers the silencing mechanism directly to liver cells. This mediator enables functional restoration through gene expression modulation, providing an alternative to transplantation that avoids associated complications
3Reliability
If SOX4 expression is suppressed using AAV8-shRNA, then bile duct development is improved, but the treatment complexity increases
Solution Approach 1:
The shRNA system employs self-service through endogenous RNA interference mechanisms. Once the AAV8 vector delivers the shRNA sequence, the cell's own molecular machinery processes the hairpin RNA into siRNA and mediates target gene silencing autonomously, improving bile duct development without requiring complex external intervention systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV8-based SOX4 reduction therapy significantly improves bile duct paucity and liver damage, potentially averting the need for liver transplantation in ALGS patients.
Implementation Method 1
Administering AAV8 vectors containing shRNA targeting SOX4 to reduce its expression and activity
Data Source
AI summary
Embodiments of the disclosure encompass methods and compositions related to treatment for individuals that have bile duct paucity, such as individuals with Alagille Syndrome. The methods and compositions relate to use of inhibitory agents that target SOX4 expression to reduce it or that target SOX4 or to reduce its activity. Specific embodiments include AAV8 vectors that encode an shRNA that targets SOX4.